Translational Medicine Reports <p><strong>Translational Medicine Reports</strong> is a peer-reviewed international journal publishing articles in the field of molecular biology, biochemistry and nanotechnology applied to the treatment of chronic-degenerative diseases including diabetes, cancer, neurological, cardiovascular and metabolic disorders. Aim of the Journal is to contribute to bridging the gap between basic research and clinical applications from an interdisciplinary perspective. <strong>Translational Medicine Reports</strong> addresses researchers and managers in academia, biotechnology and pharmaceutical industry researchers, physician scientists, <em>etc.</em> Original Articles with interdisciplinary topics, Reviews, Editorials, From Bench-to-Bedside Articles, Conference Proceedings, and Letters to the Editor are welcome. Every article published in the Journal will be peer-reviewed by experts in the field and selected by members of the Editorial Board.&nbsp;</p> <p><strong>The journal is completely free: no charge for publication, as it is supported by private funds.</strong></p> PAGEPress Scientific Publications, Pavia, Italy en-US Translational Medicine Reports 2532-1250 <p><strong>PAGEPress</strong> has chosen to apply the&nbsp;<a href="" target="_blank" rel="noopener"><strong>Creative Commons Attribution NonCommercial 4.0 International License</strong></a>&nbsp;(CC BY-NC 4.0) to all manuscripts to be published.<br><br> An Open Access Publication is one that meets the following two conditions:</p> <ol> <li>the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li> <li>a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li> </ol> <p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.</li> </ol> Evaluation of hepatitis B viraemia and corresponding antibodies among infected patients attending Abuja Teaching Hospital, Nigeria <p>In most under-developed and developing countries, diagnosis and treatment of hepatitis B relied mainly on detection of hepatitis B virus (HBV) serological biomarkers. The reliability of these markers in comparison with HBV DNA viral load is required to review their diagnostic value. Thus, this study investigated the serological and HBV viral load profile of persons with hepatitis B attending the University of Abuja Teaching Hospital, Gwagwalada, Nigeria. Attributes of hepatitis B-infected participants (February-May, 2018) were assessed. They included hepatitis B antigens (HBsAg, HBeAg), antibodies (HBsAb, HBcAb, HBeAb) and HBV DNA, using rapid immunichromatigraphical and real-time polymerase chain reaction (qPCR), respectively. Structured questionnaires were used to collate participants biodata. Out of 53 participants, 30 were male and 23 were female. 90.6% (48/53) were positive for HBsAg, 28.3% (15/53) were positive for HBsAb, 60.4% (32/53) were positive for HBcAb, 17.0% (9/53) were positive for HBeAg, while HBeAb was detected in 58.5% (31/53). HBV DNA was significantly associated with HBcAb (χ<sup>2</sup>=28.622, P=0.000), HBeAg (χ<sup>2</sup>=11.820, P=0.008), and HBeAb (χ<sup>2</sup>=16.440, P=0.001). The on-site point of care serological test has significant impact in diagnosis and monitoring Hepatitis B when compared to qPCR.</p> Anthony Uchenna Emeribe Idris Nasir Abdullahi Amos Dangana Iduda Ojeamiren Abubakar Umar Anka Abdurrahman El-Fulaty Ahmad ##submission.copyrightStatement## 2019-10-31 2019-10-31 3 2 10.4081/tmr.8423 An atypical manifestation of lymph node tuberculosis: A case report <p>Tuberculosis is a chronic granulomatous infection caused by <em>Mycobacterium tuberculosis</em>. Since the 80’s, new cases have been increasing especially in developed countries because of spreading of HIVinfection, immunodeficiency and immigration phenomenon. Cervical lymphadenitis is the most frequent localization of extrapulmonary tuberculosis. Clinical manifestations consist in a slow growth and painless swelling of a single or multiple neck nodes, generally unilateral, with rare manifestations of fistulization and of systemic symptoms. Diagnosis is performed by fine-needle aspiration cytology (FNAC) or excisional biopsy integrated by Ziehl-Neelsen stain and Mycobacteria culture. A 57-year-old male patient affected by a right-side large laterocervical swelling. The patient referred that almost one month before he noted the onset of the lesion sizing about 1 cm, so he treated it with antibiotic association of amoxicillin and clavulanate acid without any improvement. The lesion quickly doubled its size, became painful and hyperemic the skin above it. Because of the clinical worsening, the patient undergone to neck ultrasonography that showed a neck mass sizing about 50×25 mm. He began a new antibiotic therapy with Ceftriaxone intra muscle, with no modifications of the lesion. Few days later his clinical conditions drastically got worse - increasing pain and skin fistulization. So he practiced a magnetic resonance imaging of the neck that showed a massive suppurated lesion of the neck. The patient was hospitalized in our Otolaryngology Unit where he began a diagnostic <em>iter</em> in order to clarify the nature of the lesion and differentiate between neoplastic/lymphoproliferative lesion and an infective one. After a biopsy of the lesion, the hysthopatologic examination reported the presence of dense mononuclear cell infiltrate surrounding a set of Langerhans cells, so our diagnostic suspect was addressed to extrapulmonary tuberculosis. The authors report a case of a healthy man without risk factors for tuberculosis infection, come to our attention with a large and aggressive unilateral tubercular cervical lymphadenitis, skin fistulization and no systemic symptoms. To make diagnosis of tubercular lymphadenitis, we sustain that biopsy is still the gold standard if FNAC is in doubt.</p> Stefania De Luca Giuliano Sequino Flavia Oliva Roberto Varriale Giovanni Motta Viviana Allocca Maria Cardone Marco Perrella Filippo Ricciardiello ##submission.copyrightStatement## 2019-08-30 2019-08-30 3 2 10.4081/tmr.8418